These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20472448)

  • 1. Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.
    Li F; Zhu Q; Zhang Y; Feng Y; Leng Y; Zhang A
    Bioorg Med Chem; 2010 Jun; 18(11):3875-84. PubMed ID: 20472448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
    Haynes NE; Corbett WL; Bizzarro FT; Guertin KR; Hilliard DW; Holland GW; Kester RF; Mahaney PE; Qi L; Spence CL; Tengi J; Dvorozniak MT; Railkar A; Matschinsky FM; Grippo JF; Grimsby J; Sarabu R
    J Med Chem; 2010 May; 53(9):3618-25. PubMed ID: 20405948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.
    Iino T; Tsukahara D; Kamata K; Sasaki K; Ohyama S; Hosaka H; Hasegawa T; Chiba M; Nagata Y; Eiki J; Nishimura T
    Bioorg Med Chem; 2009 Apr; 17(7):2733-43. PubMed ID: 19282189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.
    Bebernitz GR; Beaulieu V; Dale BA; Deacon R; Duttaroy A; Gao J; Grondine MS; Gupta RC; Kakmak M; Kavana M; Kirman LC; Liang J; Maniara WM; Munshi S; Nadkarni SS; Schuster HF; Stams T; St Denny I; Taslimi PM; Vash B; Caplan SL
    J Med Chem; 2009 Oct; 52(19):6142-52. PubMed ID: 19746978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
    Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
    Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
    Bertram LS; Black D; Briner PH; Chatfield R; Cooke A; Fyfe MC; Murray PJ; Naud F; Nawano M; Procter MJ; Rakipovski G; Rasamison CM; Reynet C; Schofield KL; Shah VK; Spindler F; Taylor A; Turton R; Williams GM; Wong-Kai-In P; Yasuda K
    J Med Chem; 2008 Jul; 51(14):4340-5. PubMed ID: 18588279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators.
    Charaya N; Pandita D; Grewal AS; Lather V
    Comput Biol Chem; 2018 Apr; 73():221-229. PubMed ID: 29518630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and pharmacological evaluation of 2-(4-sulfonylphenyl)-2-[(E)-pyrrolidin-1-ylimino]-N-thiazoleacetamides as glucokinase activators.
    Sugama H; Matsudaira T; Yanagisawa H; Ohashi R; Nawano M; Yasuda K; Takayama H
    Bioorg Med Chem Lett; 2020 Aug; 30(15):127249. PubMed ID: 32527453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in glucokinase activators for the treatment of type 2 diabetes.
    Pal M
    Drug Discov Today; 2009 Aug; 14(15-16):784-92. PubMed ID: 19520181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators.
    Takahashi K; Hashimoto N; Nakama C; Kamata K; Sasaki K; Yoshimoto R; Ohyama S; Hosaka H; Maruki H; Nagata Y; Eiki J; Nishimura T
    Bioorg Med Chem; 2009 Oct; 17(19):7042-51. PubMed ID: 19736020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators.
    Mao W; Ning M; Liu Z; Zhu Q; Leng Y; Zhang A
    Bioorg Med Chem; 2012 May; 20(9):2982-91. PubMed ID: 22459213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel glucokinase activators: a patent review (2008 - 2010).
    Sarabu R; Berthel SJ; Kester RF; Tilley JW
    Expert Opin Ther Pat; 2011 Jan; 21(1):13-33. PubMed ID: 21155690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.
    Wang Z; Shi X; Zhang H; Yu L; Cheng Y; Zhang H; Zhang H; Zhou J; Chen J; Shen X; Duan W
    Eur J Med Chem; 2017 Oct; 139():128-152. PubMed ID: 28800453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a new class of glucokinase activators through structure-based design.
    Hinklin RJ; Boyd SA; Chicarelli MJ; Condroski KR; DeWolf WE; Lee PA; Lee W; Singh A; Thomas L; Voegtli WC; Williams L; Aicher TD
    J Med Chem; 2013 Oct; 56(19):7669-78. PubMed ID: 24015910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators.
    Ishikawa M; Nonoshita K; Ogino Y; Nagae Y; Tsukahara D; Hosaka H; Maruki H; Ohyama S; Yoshimoto R; Sasaki K; Nagata Y; Eiki J; Nishimura T
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4450-4. PubMed ID: 19540111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic activation of N-thiazol-2-yl benzamide as glucokinase activators: Impacts of glutathione trapping on covalent binding.
    Iino T; Hashimoto N; Hasegawa T; Chiba M; Eiki J; Nishimura T
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1619-22. PubMed ID: 20138764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.
    Aicher TD; Balkan B; Bell PA; Brand LJ; Cheon SH; Deems RO; Fell JB; Fillers WS; Fraser JD; Gao J; Knorr DC; Kahle GG; Leone CL; Nadelson J; Simpson R; Smith HC
    J Med Chem; 1998 Nov; 41(23):4556-66. PubMed ID: 9804695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
    Vu CB; Bemis JE; Disch JS; Ng PY; Nunes JJ; Milne JC; Carney DP; Lynch AV; Smith JJ; Lavu S; Lambert PD; Gagne DJ; Jirousek MR; Schenk S; Olefsky JM; Perni RB
    J Med Chem; 2009 Mar; 52(5):1275-83. PubMed ID: 19199480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
    Onda K; Shiraki R; Ogiyama T; Yokoyama K; Momose K; Katayama N; Orita M; Yamaguchi T; Furutani M; Hamada N; Takeuchi M; Okada M; Ohta M; Tsukamoto S
    Bioorg Med Chem; 2008 Dec; 16(23):10001-12. PubMed ID: 18952447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.